Abstract: The present invention relates to an ultra-low power (ULP) MOS diode. The diode has a first and a second terminal. It comprises an n-MOS transistor having a channel, a first N+ doped diffusion region at one extremity of the channel and a second N+ diffusion region at the other extremity of the channel, and a p-MOS transistor having a channel and a first P+ doped diffusion region at one extremity of the channel and a second P+ diffusion region at the other extremity of the channel. The first N+ diffusion region of the n-MOS transistor is coupled to the first P+ diffusion region of the p-MOS transistor, the gate of the n-MOS transistor is coupled to the second P+ diffusion region of the p-MOS transistor, and the gate of the p-MOS transistor is coupled to the second N+ diffusion region of the n-MOS transistor.

Abstract: The invention relates to a method of creating pores in a polymer material in sheet form or a polymer layer such as a thin film with a thickness equal to around 100 nanometers, previously deposited on a metallic base. The invention further relates to a method of creating pores in a polymer material in sheet form, such as polycarbonate or any other equivalent material, the said method making it possible to obtain porous areas with controllable sizes and shapes, these areas being distributed according to densities and locations which can also be controlled.

Abstract: The present invention relates to a LO-CD2a antibody and methods of using such antibodies or molecules that bind to the same epitope (or a portion thereof) to prevent and inhibit an immune response in human patients, preferably, where the immune response is mediated by the activation and proliferation of T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody to a human patient will prevent or inhibit graft rejection, graft versus host disease or autoimmune disease.

Abstract: The present invention is drawn to methods of enhancing bioavailability, pulmonary absorption and/or optimal dosing of a biologically active agent. The methods of the invention enhance the pulmonary absorption and bioavailability of a biologically active agent by administering to the pulmonary system of a subject, a biologically active agent and a macrophage inhibiting agent that is suitable for administration to a subject's pulmonary system.

Abstract: The present invention is related to an isolated and purified peroxisome-associated polypeptide. The present invention is also related to the nucleotide sequence encoding said amino sequence, the inhibitor directed against said sequences and their use in the diagnosis, treatment, and/or prevention of lung injuries or diseases and oxidative stress-related disorders.

Abstract: The present invention is related to a pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a recombinant of caveolin-1, a nucleic acid encoding the partial or total amino acid sequence of caveolin-1, or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of caveolin-1, an agonist or an antagonist or a competitive inhibitor of caveolin-1, a recombinant hsp90, a nucleic acid encoding the partial or total amino acid sequence of hsp90 or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of hsp90, an agonist or an antagonist or a competitive inhibitor of hsp90, a recombinant of Akt, a nucleic acid encoding the partial or total amino acid sequence of Akt, or an analogue thereof or a pharmacologically acceptable derivative thereof, a

Abstract: A differential amplifier is described comprising an input branch for receiving differential and common mode input signal components; an output branch providing differential and common mode output signal components; and the differential amplifier being adapted to set a relationship between the magnitude of the common mode output signal component level of the amplifier with respect to the magnitude of the common mode input signal component level to the input stage so that the common mode output signal component level intrinsically follows the common mode input signal component level as a common mode follower without using feedback control of the common mode output signal component. Also an asymmetrical amplifier is described which may be advantageously used as a component of the differential amplifier.

Abstract: Although the mechanism of induction of apoptosis through antibody dependent cellular cytotoxicity (ADCC) mediated by NK cells is well understood, little is known about the fate of the reactive NK cells. Nevertheless, it has been shown that NK cells previously activated by IL-2, but not naive NK cells, died by apoptosis after Fc&ggr;RIIIa crosslinking, or after engagement in cytolytic functions. It is demonstrated that apoptosis of naive NK cells is also observed after stimulation with a rat IgG2b anti CD2 mAb (LO-CD2a/BTI-322) or anti HLAI (LO-HLA-1)mAb. The NK apoptosis is rapid (within minutes), Fas-ligand and mRNA synthesis independent and does not require a cell contact. The intracellular mechanism of NK cell apoptosis is calcium, PKC and PLA2 dependent but calcineurin and P13 kinase independent. We suggest that NK cell apoptosis results from the crosslinking on the same cell surface of CD2 or HLA-I molecules and Fc&ggr;RIIIa that exhibits a high affinity for the rat IgG2b isotype.

Abstract: Pillared trioctahedral micas and/or vermiculites are prepared. The process includes a conditioning operation for the partial reduction of the layer charge through an accelerated weathering process, and also includes a pillaring operation.

Abstract: A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation of T-cells or natural killer cells.

Abstract: A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation of T-cells or natural killer cells.

Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.

Abstract: The present invention relates to a chimeric target molecule having an activity which can be regulated or modulated by a binding molecule. The invention also relates to methods of using the chimeric target molecule to detect the presence and/or amount of a desired analyte in a sample. The analyte is a binding molecule, or a competitor of a binding molecule, which binding molecule, upon binding to the target molecule, alters the activity of the target molecule in a detectable way. In one aspect of the invention, a binding molecule binds to the chimeric molecule, inactivating it. An analyte in a test sample competes and/or displaces the binding molecule from the chimera, reactivating it. The reappearance of activity in the presence of the analyte indicates its existence in the test sample existence and amount. Another aspect of the invention relates to a binding molecule which regulates a chimeric target molecule and methods of producing it.

Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.

Abstract: A pharmaceutical, cosmetic, and/or food composition containing a pyrazine derivative useful for preparing a medicament for preventing and/or treating pathologies related to the activity of oxygen promoters or for treating cancer tumors. The pathologies which can be treated include inflammatory diseases, carcinogenic diseases, atherosclerosis, or cancerous tumors. The pyrazine may be coelenteramine or its derivatives.

Abstract: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and circulating blood.

Abstract: Pillared trioctahedral micas and/or vermiculites are prepared. The process includes a conditioning operation for the partial reduction of the layer charge through an accelerated weathering process, and also includes a pillaring operation.

Abstract: A pharmaceutical, cosmetic and/or food composition includes a pyrazine derivative of formula (I) or (II), and/or a precursor thereof of formula (III). The composition is used for treatment of pathologies associated with prooxidant agents.

Abstract: The present invention relates to recombinant Yersinia and the use thereof for delivery of proteins into eukaryotic cells, including related compositions and methods of treatment and related assays.

Abstract: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (z) linked to a terminal group (W), characterized in that the linkage in the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and the circulating blood.